Background/aim: Familial Mediterranean fever (FMF), the most common autoinflammatory disease in children, is characterized by recurrent febrile episodes. FMF is known to progress with chronic inflammation, particularly during attack periods. This study aimed to investigate the relationship of S100A12, an inflammatory marker, with attacks and inflammatory events in FMF patients.
Materials And Methods: The study included 57 patients diagnosed with FMF, 43 in an attack-free period and 14 in an attack period, and 31 healthy children as the control group. Only white blood cell (WBC) count, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), and S100A12 level were analyzed in the control group. In addition, serum amyloid A (SAA), and fibrinogen levels were measured, and a mutation analysis was performed in the patient group. The results were compared among the attack-free period, acute attack FMF and control groups.
Results: The mean age of patients and control group was 10 (2.5–18) and 9.5 (2.5–16) years, respectively. The CRP (p = 0.001), S100A12 (p = 0.003) and ESR (p= 0.001) values differed significantly between the FMF and control groups. S100A12 level (p = 0.027), WBC count (p = 0.003), CRP level (p = 0.0001), ESR (p = 0.004), and fibrinogen level (p = 0.001) differed significantly between the acute attack and attack-free period groups. SAA level (p = 0.05), ESR (p = 0.001), fibrinogen level (p = 0.001), WBC count (p = 0.001), and S100A12 level (p = 0.027) were higher in M694V homozygous FMF patients than in other FMF patients.
Conclusion: Patients with FMF had higher S100A12 levels than the control group, while the mean S100A12 concentration was higher in acute attack period patients than in attack-free period patients. S100A12 level might be an important indicator in the monitoring of chronic inflammation in patients with FMF.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283463 | PMC |
| http://dx.doi.org/10.3906/sag-2009-187 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcutaneous electrical nerve stimulation of the occipital nerves as treatment for chronic cluster headache.
Headache
December 2024
Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark.
Background: Chronic cluster headache (CCH) is an excruciatingly painful condition that can be difficult to treat sufficiently with the available medical treatment options. The greater occipital nerves (GON) are of major interest in treating CCH, and various invasive treatment modalities, such as stimulating or blocking the nerves, have been applied. Because the terminal segment of the GON has a superficial course, the nerve is also accessible for non-invasive transcutaneous stimulation.
View Article and Find Full Text PDFThe real-world impact of biologics for NMOSD: A retrospective single-center study compared with natural course and conventional treatments in Japanese.
Mult Scler Relat Disord
December 2024
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Background: Neuromyelitis optica spectrum disorder (NMOSD), a central nervous system inflammatory disease associated with aquaporin-4 immunoglobulin G (AQP4-IgG), is conventionally treated with oral steroids and immunosuppressants (IS) in Japan. Several biologics which show great efficacy in the clinical trials have been developed recently. However, studies on their efficacy, especially those comparing them with conventional treatments in real-world situations are lacking.
View Article and Find Full Text PDFCRISPR-Based Therapy for Hereditary Angioedema.
N Engl J Med
October 2024
From Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam (D.M.C., R.S.P); Cambridge University Hospitals, NHS Foundation Trust, Cambridge, United Kingdom (P.G.); the Institute of Allergology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, and Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin (M.M.), and the Department of Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt (E.A.-P.) - all in Germany; the Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney (C.H.K.); University of Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000, INSERM, and the Department of Internal Medicine and Clinical Immunology, CHU Lille, National Reference Center for Angioedema (CREAK), Lille (D.L.), and CREAK, Angioedema Center of Reference and Excellence (ACARE), Grenoble Alpes University Hospital, and the Translational Research in Autoimmunity and Inflammation Arm (T-RAIG), French National Center for Scientific Research (CNRS), Grenoble (L.B.) - all in France; Intellia Therapeutics, Cambridge, MA (D.M., J.S.B., M.Y.S., A.G., Y.X., A.M.A., D.L.); and the Department of Immunology, Auckland City Hospital, and the Department of Medicine, University of Auckland - both in Auckland, New Zealand (K.L., H.J.L.).
Background: Hereditary angioedema is a rare genetic disease characterized by severe and unpredictable swelling attacks. NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 targets the gene encoding kallikrein B1 ().
View Article and Find Full Text PDFLanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report.
Front Immunol
October 2024
Internal Medicine Department, Fatebenefratelli Hospital, Milan, Italy.
Article Synopsis
- Cardiovascular diseases are the leading cause of death in patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH), often exacerbated by long-term treatments like attenuated androgens that can increase cardiovascular risk.
- A case study of a 56-year-old HAE-C1INH patient with numerous health issues, including kidney impairment and hypertension, showcased a successful transition from traditional androgen therapy to the modern treatment, lanadelumab, starting in 2020.
- After beginning lanadelumab, the patient saw no angioedema attacks, experienced a decrease in cardiovascular risk factors like cholesterol and body mass index, and improved overall health outcomes, indicating this treatment's effectiveness and safety.
Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
Allergy
October 2024
Allergy, Asthma and Immunology, Department of Medicine and Pediatrics, Penn State University, Hershey, Pennsylvania, USA.
Article Synopsis
- Hereditary angioedema (HAE) is a chronic disease requiring effective long-term preventive treatments, prompting a study to evaluate the safety and efficacy of garadacimab, a new medication for HAE.
- In an interim analysis of the ongoing phase 3 VANGUARD study, involving 161 patients, most treatment-emergent adverse events (TEAEs) were mild, with injection-site reactions being the most common, and no serious complications linked to garadacimab were reported.
- The results showed a significant reduction in HAE attacks, with 60% of patients remaining attack-free, indicating that garadacimab offers a safe and effective long-term treatment option for patients with
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!